Lead Sponsor

OccuLogix

Age

50 - 85 years

Sex

ALL

Healthy Volunteers

No

•Study eye must have a diagnosis of non-exudative, "Dry", AMD with equivalent drusen surface area of approximately 31,000 µm2 \[e.g. at least 10 soft, semi-soft intermediate size ≥63µm or at least 3 drusen size ≥125 µm within 3,000 µm of the fovea documented on macular exam, retinal angiography and fundus photographs as determined by the reading center. ETDRS BCVA of 20/40 - 20/100 inclusive

•Either eye with previous or active sub-retinal neovascularization (SRNV) or choroidal neovascularization (CNV)
•Pigment epithelial detachment (PED) within 500 µm of the fovea
•Either eye with a diagnosis of exudative (wet) AMD
•Subjects having undergone cataract surgery less than 3 months prior to enrollment without an open posterior capsule
•Uncontrolled hypertension and/or diabetes
•Subjects with prolonged PT/PTT (unless the subject is taking warfarin), hematocrit \<35%, evidence of active bleeding, platelet count \<100,000/ml

Related studies

NCT00473642 · Age-Related Maculopathy, Choroidal Neovascularization

NCT01577381 · Age-Related Maculopathy

NCT00759044 · Age-Related Maculopathy, Diabetic Macular Edema

NCT00051129 · Macular Degeneration, Maculopathy, Age-Related, and more

NCT01122511 · Subfoveal Choroidal Neovascularization, Age-Related Maculopathy

Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis